Northeast Pharmaceutical Group announcement, the company held a board of directors meeting on November 5, 2024, and passed a resolution to sign a share acquisition agreement. The company will use its own funds in cash to acquire 70% equity of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. for approximately 0.187 billion yuan. Dingcheng Peptide Source is a research and development enterprise focusing on solid tumor cell therapy products, with a unique sequence discovery platform and a complete technical platform. This acquisition will help Northeast Pharmaceutical Group optimize its business structure, quickly enter the field of specific cell immunotherapy, and cultivate new business growth points.